Stock RV6 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Charles River Laboratories International, Inc. Deutsche Boerse AG

Equities

RV6

US1598641074

Real-time Estimate Tradegate
Other stock markets
 07:00:01 02/05/2024 BST 		5-day change 1st Jan Change
217 EUR +0.44% Intraday chart for Charles River Laboratories International, Inc. +1.74% +0.93%
04-25 FibroBiologics, Inc. Plans to Collaborate with Charles River Laboratories to Manufacture Fibroblast-Based Spheroids CI
04-24 Charles River Laboratories Files Supplement to Definitive Proxy Statement with the Securities and Exchange Commission CI

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The firm trades with high earnings multiples: 28.72 times its 2024 earnings per share.
  • With an enterprise value anticipated at 3.3 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
+0.93% 11.95B -
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.67% 42.4B
B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 40.04B
A
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.55% 24.94B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.66% 18.96B
B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.96% 12.3B
C+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+16.03% 11.32B
B+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-4.80% 11.55B
B+
QIAGEN N.V. Stock Qiagen N.V.
-4.38% 9.5B
A
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. CRL Stock
  4. RV6 Stock
  5. Ratings Charles River Laboratories International, Inc.